Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Joerger M, Kloft C.
Mc Laughlin AM, et al. Among authors: kopp c.
Cancer Chemother Pharmacol. 2024 Sep;94(3):349-360. doi: 10.1007/s00280-024-04679-z. Epub 2024 Jun 15.
Cancer Chemother Pharmacol. 2024.
PMID: 38878207
Free PMC article.
Clinical Trial.